Rituximab Biosimilar Immunological Preparation from Japan
A mixed immunological product containing rituximab monoclonal antibodies used for treating non-Hodgkin lymphoma and rheumatoid arthritis. Classified under HTS 3002.14.0010 as it is an immunological product containing monoclonal antibodies, not put up in measured doses or retail packings. It consists of multiple components including the antibody and stabilizers for therapeutic use.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Verify product contains monoclonal antibodies via certificate of analysis; ensure biotech origin documentation
• Comply with FDA biologics import requirements including lot release and proper cold chain validation
• Avoid misclassification as unmixed by confirming mixture of antibody with excipients; declare exact composition